Kodiak Sciences Inc.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Christopher L. JacobsHouse · R · NY |
KODKodiak Sciences Inc. · Stock |
Sale $1,001 - $15,000 |
Dec 12, 2022 | Nov 8, 2022 | Filing ↗ |
Christopher L. JacobsHouse · R · NY |
KODKodiak Sciences Inc. · Stock |
Purchase $1,001 - $15,000 |
Sep 9, 2022 | Jul 18, 2022 | Filing ↗ |
Whale Activity
- Increased61
- New47
- Held24
- Decreased75
- Closed32
- No prior filing10
| Filer | Shares | Value | Change |
|---|---|---|---|
| BAKER BROS. ADVISORS LP | 21.9M | $2.07B | increased |
| BlackRock, Inc. | 3.8M | $361.6M | decreased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.9M | $278.1M | decreased |
| STATE STREET CORP | 2.2M | $211.3M | decreased |
| GOLDMAN SACHS GROUP INC | 2.0M | $188.7M | decreased |
| T. Rowe Price Investment Management, Inc. | 2.0M | $186.9M | increased |
| Janus Henderson Group Ltd. | 1.9M | $178.0M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.8M | $168.5M | decreased |
| RTW INVESTMENTS, LP | 1.5M | $141.1M | held |
| Boxer Capital Management, LLC | 1.5M | $140.1M | held |
| TCG Crossover Management, LLC | 1.4M | $137.0M | held |
| BRAIDWELL LP | 1.1M | $102.9M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP / 667, L.P. / Baker Bros. Advisors (GP) LLC / Baker Brothers Life Sciences LP / BAKER FELIX / BAKER JULIANDirector · Director | Purchase | +81.7K | $98.51 | $8.1M | Nov 5, 2026 | Form 4 ↗ |
| BAKER BROS. ADVISORS LP / 667, L.P. / Baker Bros. Advisors (GP) LLC / Baker Brothers Life Sciences LP / BAKER FELIX / BAKER JULIANDirector · Director | Purchase | +4,703 | $98.51 | $463K | Nov 5, 2026 | Form 4 ↗ |
| BAKER BROS. ADVISORS LP / 667, L.P. / Baker Bros. Advisors (GP) LLC / Baker Brothers Life Sciences LP / BAKER FELIX / BAKER JULIANDirector · Director | Purchase | +8,742 | $98.51 | $861K | Nov 4, 2026 | Form 4 ↗ |
| BAKER BROS. ADVISORS LP / 667, L.P. / Baker Bros. Advisors (GP) LLC / Baker Brothers Life Sciences LP / BAKER FELIX / BAKER JULIANDirector · Director | Purchase | +151.9K | $98.51 | $15.0M | Nov 4, 2026 | Form 4 ↗ |
| BORGESON JOHN A.Chief Financial Officer | Sale | −8,514 | $87.67 | $746K | Oct 21, 2026 | Form 4 ↗ |
| BORGESON JOHN A.Chief Financial Officer | Sale | −7,623 | $89.74 | $684K | Oct 21, 2026 | Form 4 ↗ |
| BORGESON JOHN A.Chief Financial Officer | Sale | −5,101 | $90.98 | $464K | Oct 21, 2026 | Form 4 ↗ |
| BORGESON JOHN A.Chief Financial Officer | Sale | −2,985 | $91.76 | $274K | Oct 21, 2026 | Form 4 ↗ |
| BORGESON JOHN A.Chief Financial Officer | Sale | −2,000 | $93.71 | $187K | Oct 21, 2026 | Form 4 ↗ |
| BORGESON JOHN A.Chief Financial Officer | Sale | −2,000 | $92.66 | $185K | Oct 21, 2026 | Form 4 ↗ |
| BORGESON JOHN A.Chief Financial Officer | Sale | −1,677 | $89.20 | $150K | Oct 21, 2026 | Form 4 ↗ |
| BORGESON JOHN A.Chief Financial Officer | Sale | −100 | $94.91 | $9K | Oct 21, 2026 | Form 4 ↗ |
| 667, L.P.Director · 10% owner | Purchase | +1,416 | $85.89 | $122K | Sep 29, 2026 | Form 4 ↗ |
| 667, L.P.Director · 10% owner | Purchase | +84 | $85.89 | $7K | Sep 29, 2026 | Form 4 ↗ |
| 667, L.P.Director · 10% owner | Purchase | +20.0K | $85.40 | $1.7M | Sep 29, 2026 | Form 4 ↗ |
| 667, L.P.Director · 10% owner | Purchase | +1,195 | $85.40 | $102K | Sep 29, 2026 | Form 4 ↗ |
| 667, L.P.Director · 10% owner | Purchase | +10.4K | $84.24 | $874K | Sep 29, 2026 | Form 4 ↗ |
| 667, L.P.Director · 10% owner | Purchase | +619 | $84.24 | $52K | Sep 29, 2026 | Form 4 ↗ |
| 667, L.P.Director · 10% owner | Purchase | +196.6K | $89.86 | $17.7M | Sep 28, 2026 | Form 4 ↗ |
| 667, L.P.Director · 10% owner | Purchase | +11.7K | $89.86 | $1.1M | Sep 28, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.5M | $58.3M | 0.54% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.3M | $50.2M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.0M | $39.8M | 0.05% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.0M | $39.5M | 0.33% | Jun 30, 2026 |
| Artisan International Small-Mid Fund Artisan Partners Funds Inc. | 596.0K | $23.2M | 0.91% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 590.8K | $23.0M | 0.16% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC. | 498.3K | $19.4M | 0.20% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 475.6K | $18.5M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 430.5K | $17.9M | 0.05% | Jul 31, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 426.5K | $16.6M | 0.18% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list KOD's shares (CUSIP 50015M109), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Alex SilversteinSCHEDULE 13G/A · passive (13G) · 1.8M shares2.9%
Nov 16, 2026 · ↗ - Sirenia Capital Management LPSCHEDULE 13G/A · passive (13G) · 1.8M shares2.9%
Nov 16, 2026 · ↗ - T. Rowe Price Associates, Inc.SCHEDULE 13G/A · passive (13G) · 2.9M shares4.7%
Nov 16, 2026 · ↗ - Felix J. BakerSCHEDULE 13D/A · activist (13D) · 22.0M shares35.0%
Sep 30, 2026 · ↗ - Julian C. BakerSCHEDULE 13D/A · activist (13D) · 22.0M shares35.0%
Sep 30, 2026 · ↗ - Baker Bros. Advisors (GP) LLCSCHEDULE 13D/A · activist (13D) · 22.0M shares35.0%
Sep 30, 2026 · ↗ - Baker Bros. Advisors LPSCHEDULE 13D/A · activist (13D) · 22.0M shares35.0%
Sep 30, 2026 · ↗ - T. Rowe Price Associates, Inc.SCHEDULE 13G · passive (13G) · 3.2M shares5.2%
Aug 14, 2026 · ↗ - Alex SilversteinSCHEDULE 13G · passive (13G) · 3.5M shares5.7%
May 15, 2026 · ↗ - Sirenia Capital Management LPSCHEDULE 13G · passive (13G) · 3.5M shares5.7%
May 15, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming Kodiak Sciences Inc. as the client.
Government Contracts
No federal contract awards found for Kodiak Sciences Inc..
U.S. Patents
No USPTO patent applications found for Kodiak Sciences Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$234.4M | -$186.8M | -$277.3M | -$341.4M | -$267.1M |
| Net income | -$230.0M | -$176.2M | -$260.5M | -$333.8M | -$267.0M |
| Diluted EPS | -$4.32 | -$3.35 | -$4.97 | -$6.39 | -$5.16 |
| Operating cash flow | -$136.0M | -$117.3M | -$154.2M | -$206.5M | -$182.3M |
| Cash and equivalents | $209.9M | $168.1M | $285.5M | $190.4M | $731.5M |
| Total assets | $351.5M | $335.6M | $479.4M | $666.6M | $904.2M |
| Total liabilities | $194.2M | $185.3M | $213.6M | $230.5M | $240.9M |
| Shareholders' equity | $157.4M | $150.3M | $265.8M | $436.2M | $663.3M |
As Kodiak Sciences Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 31, 2026 ↗
Stock Splits
No stock splits in KOD's price history.

